Get the Stockscreener App
6.25
5.73%
-0.38
After Hours:
6.56
0.31
+4.96%
Olema Pharmaceuticals Inc stock is traded at $6.25, with a volume of 511.21K.
It is down -5.73% in the last 24 hours and up +13.64% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$6.63
Open:
$6.63
24h Volume:
511.21K
Relative Volume:
0.52
Market Cap:
$464.02M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-2.907
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-1.26%
1M Performance:
+13.64%
6M Performance:
-55.16%
1Y Performance:
-59.66%
1-Day Range:
$6.23
$6.63
1-Week Range:
$5.8095
$6.7021
52-Week Range:
$4.60
$16.77
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
6.25 | 464.02M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
There is no way Olema Pharmaceuticals Inc (OLMA) can keep these numbers up - SETE News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
OLMAOlema Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Olema Pharma's Strategic Talent Acquisition: $1.7M in Equity Grants Signals Growth Push - StockTitan
Olema Pharmaceuticals Inc (OLMA) Becoming More Attractive for Investors - Knox Daily
Are Olema Pharmaceuticals Inc (OLMA) shares a good deal now? - US Post News
Financial Metrics Exploration: Understanding Olema Pharmaceuticals Inc (OLMA) Through Ratios - The Dwinnex
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Exclusive Access: Olema Pharmaceuticals Reveals Latest Oncology Progress at Two Elite Healthcare Forums - StockTitan
HR Positive/ HER2 Negative Breast Cancer Pipeline 2024: MOA - openPR
How To Trade (OLMA) - Stock Traders Daily
JPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
JPMorgan Chase & Co. Purchases 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Holdings Increased by Hennion & Walsh Asset Management Inc. - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Consensus Target Price from Brokerages - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Form 424B5 Olema Pharmaceuticals, - StreetInsider.com
Barclays PLC Purchases 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bain Capital Life Sciences Investors, LLC Acquires Significant S - GuruFocus.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in Stock - MarketBeat
Bain Capital Life Sciences buys $1.7m in Olema Pharmaceuticals stock - Investing.com Nigeria
Olema Pharmaceuticals announces equity security exchange By Investing.com - Investing.com Australia
Olema Pharmaceuticals announces equity security exchange - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 By Investing.com - Investing.com South Africa
(OLMA) Investment Report - Stock Traders Daily
Olema Pharmaceuticals Awards New Employee Stock Options for Cancer Drug Development Team - StockTitan
Olema Pharmaceuticals stock hits 52-week low at $5.55 By Investing.com - Investing.com Australia
Olema Pharmaceuticals stock hits 52-week low at $5.55 - Investing.com India
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Geode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Geode Capital Management LLC Sells 125,170 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Barclays PLC Acquires 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateForm 8-K - Marketscreener.com
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
State Street Corp Boosts Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,616 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock - MarketBeat
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock By Investing.com - Investing.com South Africa
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock - Investing.com
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):